Keywords: nerve tissue protein S100; schizophrenia; antipsychotic agents; negative symptomatology; psychiatric status S100B, a calcium-binding protein produced by astroglial cells, is a marker of astroglial cellular integrity. It has been shown to be increased in acute brain damage and neurodegeneration. A recent study showed increased S100B levels in medicated acutely psychotic patients with schizophrenia. The study presented here included 26 drug-free patients with acute schizophrenia and 26 matched healthy controls. S100B blood concentrations were determined using a quantitative immunoassay upon admission and after 6 weeks of neuroleptic treatment. The PANSS was used to investigate psychopathology. Unmedicated schizophrenic patients showed significantly increased S100B levels compared to matched healthy controls. After 6 weeks of treatment, 11 patients showed normal S100B levels while in 15 patients the levels remained increased. These patients showed significantly higher PANSS negative scores upon admission and after 6 weeks of treatment. Schizophrenic patients display a loss of astroglial integrity which is not caused by neuroleptic medication. Continuously increased S100B levels are associated with negative symptomatology. Molecular Psychiatry (2001) 6, 445-449.
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There is continuing discussion on the neurodegenerative mechanisms which contribute to the etiopathogenesis of schizophrenia. Support for this hypothesis comes from postmortem studies and especially from recent volumetric MRI studies indicating that ventricular enlargement and hemispheric volumetric reductions may have a progressive component in patients with schizophrenia (for a review see DeLisi 1 ). Changes in brain structure and volume appear to arise from a reduction of neuritic processes (such as dendrites and synapses) rather than from a loss of neuronal or glial cell bodies (for a review see McGlashan & Hoffman 2 ). A missing link for this hypothesis is a biochemical marker for cellular integrity in the brain that can be measured during acute psychotic episodes of schizophrenic patients. S100B has the potential to serve as such a marker.
The term S100 comprises a heterogeneous family of acidic calcium-binding proteins of which the two proteins S100A1 and S100B are considered to be the most relevant members regarding neurological disease.
3 S100B predominates in the brain. S100A1 and S100B form dimeric proteins with a molecular weight of 21 kDA, which have previously been named S100a (S100A1-S100B), S100b (S100B-S100B), and S100a0 (S100A-S100A).
4 S100B is synthesized mainly by astrocytes and evolves paracrine and autocrine effects on neurons and glia. 5 In adult brains it plays a role in neuronal plasticity and long-term potentiation. Those effects appear to be mediated primarily through binding to key synaptic proteins and inhibition of their phosphorylation. S100B in particular has an important role in regulating the protein kinase C phosphorylation of GAP-43, a growth-associated protein which is involved in axonal growth and synaptogenesis during development, synaptic remodeling and long-term potentiation. S100B interacts with and stabilizes microtubule-associated proteins (MAPs), such as tau and MAP-2. Increased S100B and MAP-2 promote dendritic maturation and induce a loss of dendrites. 6 Lower concentrations of extracellular S100B act on glial and neuronal cells as a growth differentiating factor, while higher concentrations induce apoptosis. 7 Structural damage to glial cells causes leakage of S100B protein into the extracellular compartment and cerebrospinal fluid; it also causes it to enter the bloodstream. 4 Increased CSF and plasma levels of S100B have been detected after traumatic brain injury, toxic or ischemic brain damage, and in multiple sclerosis. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] S-100B is also elevated in several kinds of dementia, especially Alzheimer's disease. 5 Our group showed increased S-100B plasma levels in medicated patients suffering from schizophrenia, 18 whereas Gattaz and colleagues reported decreased S100B concentrations in medicated patients with schizophrenia. 19 In the present study we were able to investigate unmedicated or even drug-naive acutely psychotic schizophrenic patients. The patients were reinvestigated after 6 weeks of neuroleptic treatment.
The mean PANSS (Positive and Negative Syndrome Scale) total score upon admission was 86.7 ± 17.9, ranging from 55 to 127. After 6 weeks of neuroleptic treatment the mean PANSS score was 66.7 ± 17.8 (range: 36-97), indicating a significant improvement of psychopathology (Z = −3.89, P Յ 0.0001). The positive and general psychopathology subscales showed a significant decrease after 6 weeks of treatment (Z = −4.25, P Յ 0.0001; Z = −3.02, P = 0.003, respectively), while the negative subscale showed no significant change (Z = −1.05, P = 0.29, Table 1 ).
Upon admission, the S100B plasma level in schizophrenic patients (mean 0.098 g l −1 , SD 0.076) was significantly higher compared to the matched healthy controls (mean 0.034 g l ) the level of significance was no longer reached (Z = −1.92, P = 0.056). There was a significant positive correlation between the negative subscale score and the S100B concentration after 6 weeks (rho = 0.493, P = 0.02). Furthermore, intraindividual differences between negative subscale scores upon admission and after treatment were significantly correlated with the S100B concentration after 6 weeks, indicating that little change or even deterioration of the negative symptomatology was associated with high S100B levels (rho = −0.7, P Յ 0.0001).
Upon admission, 15 patients showed S100B levels that were higher than the mean levels of the healthy controls plus two standard deviations (Ͼ0.069 g l
−1
). After 6 weeks of treatment these patients had significantly higher PANSS negative scores than the patients with lower S100B upon admission (Z = −2.39, P = 0.016, Figure 2 ), while upon admission the PANSS negative scores did not differ between the groups (Z = −1.56, P = 0.12). PANSS total scores did not differ between groups either upon admission (Z = −1.38, Figure 2 PANSS negative subscale scores (mean plus SD) of schizophrenic patients after 6 weeks of treatment. Patients were grouped according to their S100B blood levels upon admission. Group A had S100B levels higher than the mean plus two standard deviations of matched healthy controls (mean: 0.034 g l ) while group B showed S100B levels lower than 0.069 g l −1
. After 6 weeks of treatment, patients with high S100B levels upon admission (group A) demonstrated significantly higher PANSS negative scores than patients with low S100B levels upon admission (group B). P = 0.18) or after 6 weeks of treatment (Z = −0.48, P = 0.65).
After 6 weeks of treatment, seven patients still had S100B levels above 0.069 g l −1 . These patients demonstrated significantly less improvement in the PANSS total (Z = −2.51, P = 0.011) and the negative subscale scores (Z = −2.55, P = 0.010) after treatment compared to patients with lower S100B levels after 6 weeks of treatment (Figure 3) .
No differences in S100B levels were detected between the group of patients treated with typical and the group treated with atypical neuroleptic drugs (Z = −0.029, P = 0.98). At both time points of investigations the S100B levels of drug-naive patients did not differ from the levels of patients with a history of neuroleptic medication (admission: Z = −0.318, P = 0.75; after 6 weeks: Z = −0.349; P = 0.73). There was no significant correlation between S100B and the dose of haloperidol equivalents after 6 weeks of treatment (rho = −0.04, P = 0.85). No sex-related differences were observed (Z = −0.18, P = 0.89). There were no significant correlations between S100B and age (rho = −0.13, P = 0.54), onset of illness (rho = −0.21, P = 0.30), or duration of illness (rho = 0.12, P = 0.57).
To our knowledge, this is the first study investigating S100B serum levels in unmedicated schizophrenic patients; it also includes a follow-up investigation after 6 weeks of neuroleptic treatment. We were able to show that S100B plasma levels are increased in unmedicated acutely psychotic schizophrenic patients as previously shown by Wiesmann et al 18 for medi- Figure 3 PANSS negative subscale scores of schizophrenic patients upon admission (day 1, unmedicated) and after 6 weeks of treatment (day 43). Patients were grouped according to their S100B blood levels after 6 weeks of treatment. Group 1 had S100B levels higher than the mean plus two standard deviations of matched healthy controls (mean: 0.034 g l ), while group 2 had S100B levels lower than 0.069 g l −1
. Patients with high S100B blood levels upon admission (group 1) showed no change in the PANSS negative score during treatment, while patients with low S100B (group 2) showed a significant improvement in negative symptomatology.
Molecular Psychiatry cated patients. Increased S100B plasma levels in schizophrenic patients are obviously not an artifact caused by neuroleptic medication. However, these results contrast with the findings of Gattaz et al 19 who reported decreased S100B plasma levels in schizophrenic outpatients, mostly treated with clozapine. Differences in the investigated patient samples could account for these discrepancies. The fact that the sample of Gattaz et al 19 included schizophrenic outpatients predominantly treated with clozapine allows the assumption that those patients were investigated in a residual, remitted or at least in a not highly acute stage of disease, whereas our sample consisted of acutely psychotic inpatients suffering from an acute episode of paranoid schizophrenia. After 6 weeks of neuroleptic treatment, the S100B levels in the total group of patients in our study did not significantly differ from healthy controls anymore. S100B plasma levels may serve as a marker for the acute stage of schizophrenic psychosis and might normalize or even decrease in a chronic stage of disease, as reported by Gattaz et al. 19 The negative dimension of the schizophrenic symptomatology is correlated with S100B plasma levels. Patients with initially high S100B plasma levels showed significantly higher PANSS negative scores after 6 weeks of treatment than patients who upon admission showed S100B levels closer to normal. Also, patients with high S100B levels after 6 weeks of treatment showed no change in the PANSS negative subscale scores, while those patients whose S100B levels returned to normal experienced a significant improvement in negative psychopathology. These findings allow the interpretation that amongst patients suffering from more severe negative symptoms, astroglial integrity is affected to a greater degree not only in an acute stage of the disease but also after 6 weeks of treatment. A loss of astroglial intactness appears to be associated with the development of negative symptoms rather than positive or general psychopathology symptoms. A restoration of astroglial integrity seems to be associated with improvement of negative symptoms.
In schizophrenia, severe negative symptoms are a main cause for an unfavorable clinical outcome leading to invalidity. Besides affective and social impairment, cognitive deficits are major factors in determining adverse outcome. Findings reporting a possible influence of cellular integrity (as indicated by S100B plasma levels) on cognitive function are therefore of special interest in this context. In neuropsychological testing, minor head injury patients with elevated S100 showed disrupted reaction time, attention and speed of information processing. 20 In head injury or stroke patients, a higher plasma concentration of S100 predicted an unfavorable clinical outcome compared to patients with lower S100 levels. [12] [13] [14] Transgenic mice with an overproduction of S100B showed significant learning deficits and behavior similar to mice with manifestations of hippocampal dysfunction. 6, 21 Increased S100B plasma levels in acute schizophrenia indicate that there might be a loss of cellular integrity in the brain in that stage of the disease, and they appear to be associated with a more severe negative psychopathology and the persistence of these symptoms. These findings seem to support the hypothesis of Lieberman et al, 22 stating that there might be a progressive degenerative component in the early phase of the disease and that poorer outcome is associated with an increase in ventricular volume over time. Future research should focus on the investigation of additional biochemical parameters, MRI findings and cognitive functions in patients with increased S100B.
Materials and methods
After written informed consent was acquired, plasma samples were taken by venipuncture from 26 in patients (10 males, 16 females, aged 20-59 years, mean age 37.0 ± 12.9 years) suffering from an acute episode of paranoid type schizophrenia (DSM-IV 295.3) and 26 age-and sex-matched healthy controls (aged 20-59 years, mean age 37.0 ± 12.9 years), who were recruited at the blood donation service of the University of Luebeck. Patients and controls were diagnosed independently by two psychiatrists according to DSM-IV criteria. No patients had received any psychotropic medication for at least 6 months prior to examination, seven patients were even drug-naive. The PANSS was used to evaluate psychopathology. All patients were examined twice by the same rater: upon admission (unmedicated), and after 6 weeks of neuroleptic treatment. Fourteen patients received typical (four bromperidole, three fluphenazine, three benperidole, three haloperidole, one flupenthixole), and 12 received atypical neuroleptic drugs (four clozapin, three olanzapine, five risperidone). The mean duration of illness was 9.96 ± 10.35 years, ranging from 0 to 39 years. The controls had no lifetime history of any psychiatric disorder. Systemic diseases (neoplasms, autoimmune diseases, infectious diseases, neurological, and cardiovascular diseases), brain injury, co-morbid psychiatric diagnosis (eg dementia) and substance abuse were excluded by taking a detailed history, reviewing charts, and performing a physical examination of patients and healthy controls.
Blood samples were centrifuged within 4 h, aliquoted, and frozen at −80°C until analysis. S-100B concentrations were determined by an immunofluorometric sandwich assay using a monoclonal anti-S-100B antibody on the solid phase and a polyclonal rabbit anti-S100 antibody for detection, as described previously. 12 The assay's lower detection limit for S-100 is 0.015 g l . The assay is specific for S-100B which predominates in the brain. 23 The intraassay (withinrun) imprecision (CVs) is 3.2% at 0.51 g l , and 2.3% at 11.4 g l . The total imprecision (between-day, CVs) is 11.5% at 0.45 g l −1 , 7.9% at 4.79 g l −1 , and 7.8% at 15.45 g l −1 . Analytical recovery ranged between 90 and 101%.
Due to the non-Gaussian distribution of our data, non-parametric tests were employed for statistical evaluation. The Wilcoxon Matched-Pairs Signed-Ranks Test, the Mann-Whitney U-Test, and the Spearman Correlation Coefficient were used as provided by the SPSS 9.0 program.
